Lundbeck appoints strategy executives
This article was originally published in Scrip
Executive Summary
Trailing an expected 18 month new medicines launch programme, Lundbeck has appointed Andreas Eggert as senior vice president for global product strategy and Klaus Abel as vice president with responsibility for commercialisation of medicines from the Danish company's partnership with Otsuka Pharmaceuticals. Since joining Lundbeck in 2010, Mr Eggert has driven marketing strategy development and execution of new medicines. He reports to president and CEO Ulf Wiinberg. Mr Abel, who will report to Mr Eggert, will have special focus on collaborative development and commercialisation of two medicines: once monthly aripiprazole for treatment of schizophrenia, and brexpiprazole (OPC-34712) for treatment of schizophrenia and major depression.